Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

Therini Bio, Inc. | 1,720 followers on LinkedIn. Immunotherapies for NEUROINFLAMMATION in diseases driven by vascular dysfunction  | Therini Bio is a clinical-stage biotech company developing immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. The Company is developing a pipeline of potential first-in-class therapies selectively targeting toxic fibrin accumulation for diseases, including Alzheimer’s disease (AD) and Diabetic Macular Edema (DME), where destructive neuroinflammation plays a central role in the disease process. The foundational science was licensed based on technology discovered in Katerina Akassoglou’s, Ph.D., laboratories at the Gladstone Institutes at the University of California San Francisco (UCSF) and formerly the University of California San Diego (UCSD).

Professor @ Gladstone & UCSF | Neuroimmunology, Neuroscience, Vascular Biology

Katerina Akassoglou

Head of Translational Sciences at Therini Bio

Aaron Kantor

General Partner & Managing Director at DFV | Healthcare VC, Entrepreneur, & Board Director

Sourav Kole

Biotech executive, company builder and board member

Tara Nickerson

Therini Bio, Inc.

Congrats to Therini founder Katerina Akassoglou and her collaborators on this significant research published today in Nature. This study further highlights the importance of therapies targeting neuroinflammation resulting from fibrin, such as those currently being developed by Therini for Alzheimer's and retinal diseases. https://lnkd.in/g8Y-akS7

Therini Bio team at ARVO this week shared updates on our pioneering approach to halt chronic neuroinflammation in diseases caused by vascular injury. Aaron Kantor , Joel Naor, MD, MSc, MBA #ARVO2024 #neuroinflammation #fibrin https://lnkd.in/g-6wdneD

Further research demonstrating how fibrin triggers neuroinflammation by JaeKyu Ryu and Therini Founder Katerina Akassoglou . Therini is developing a first-in-class immunotherapy, currently in Phase 1 studies, to neutralize the toxic effects of fibrin.

Congrats to Therini Bio's scientific founder Katerina Akassoglou on this well-deserved recognition! Stemming from this pioneering research, Therini is developing THN391 to target fibrin-driven neuroinflammation in diseases involving loss of vascular integrity including Alzheimer's disease and Diabetic Macular Edema.

We celebrate Katerina Akassoglou for her pioneering research around the role of fibrin-driven inflammation underlying a range of diseases that involve vascular dysfunction, and discovery of a fibrin-targeting immunotherapy approach to protect against neuroinflammation and neurodegeneration.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 16, 2024 8:37 PM	3c2d7083
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 16, 2024 8:37 PM	1fb2ca54
crunchbase trigger	general	Nov 16, 2024 8:37 PM	3104ab91
crunchbase profile	general	Nov 16, 2024 8:44 PM	e546e891
li profile	general	Nov 16, 2024 8:37 PM	8bf92b15
translate crunchbase fundingrounds	general
peers	general	Nov 16, 2024 8:37 PM	6f67a925
news basic	general	Nov 16, 2024 8:37 PM	5c511704
bundesanzeiger	filings
financials download nd	financials
private financials	financials

THER

COM:THERINIBIO

Therini Bio